These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15099275)

  • 1. Activated protein C in sepsis.
    Taylor FB; Kinasewitz G
    J Thromb Haemost; 2004 May; 2(5):708-17. PubMed ID: 15099275
    [No Abstract]   [Full Text] [Related]  

  • 2. Introduction: severe sepsis and drotrecogin alfa (activated).
    Artigas A; Martin CD
    Crit Care; 2007; 11 Suppl 5():S1. PubMed ID: 18269688
    [No Abstract]   [Full Text] [Related]  

  • 3. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
    Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
    Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A definite role for treatment with activated protein C in sepsis? Standard use is premature.
    Girbes AR; Polderman KH
    J Thromb Haemost; 2003 Dec; 1(12):2469-71. PubMed ID: 14675079
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on "Drotrecogin Alfa (activated) (recombinant human protein C, rhAPC) reduces host coagulopathy response in patients with severe sepsis".
    Taylor F
    Thromb Haemost; 2003 Oct; 90(4):560-1. PubMed ID: 14515171
    [No Abstract]   [Full Text] [Related]  

  • 6. Activated protein C versus protein C in severe sepsis.
    Yan SB; Dhainaut JF
    Crit Care Med; 2001 Jul; 29(7 Suppl):S69-74. PubMed ID: 11445737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis.
    Grinnell BW; Joyce D
    Crit Care Med; 2001 Jul; 29(7 Suppl):S53-60; discussion S60-1. PubMed ID: 11445735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of drotrecogin alfa activated (rhAPC).
    Jilma B; Derhaschnig U
    Thromb Haemost; 2004 May; 91(5):1050. PubMed ID: 15116270
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.
    Morris PE; Hite RD; Ohl C
    BioDrugs; 2002; 16(6):403-17. PubMed ID: 12463764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment on: "The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia" by Spiel et al.
    Messaris E; Memos N; Frantzeskaki F; Economou V; Betrosian A
    Thromb Haemost; 2006 Jun; 95(6):1048-9. PubMed ID: 16732392
    [No Abstract]   [Full Text] [Related]  

  • 11. [Activated protein C, a protein at the crossroads between coagulation and inflammation].
    Borgel D; Vieillard-Baron A
    Med Sci (Paris); 2011 May; 27(5):501-7. PubMed ID: 21609671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing sepsis-associated coagulopathy remains an enigma.
    Thachil J
    J Thromb Haemost; 2019 Oct; 17(10):1586-1589. PubMed ID: 31376202
    [No Abstract]   [Full Text] [Related]  

  • 13. Natural anticoagulant inhibitors: activated Protein C.
    Aird WC
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):161-82. PubMed ID: 15171965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis.
    Bernard G; Artigas A; Dellinger P; Esmon C; Faist E; Faust SN; Fischer CJ; Fumagalli R; grinnell BW; Sprung C
    Crit Care Med; 2001 Jul; 29(7 Suppl):S75-7. PubMed ID: 11445738
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating Histones in Sepsis: Potential Outcome Predictors and Therapeutic Targets.
    Li Y; Wan D; Luo X; Song T; Wang Y; Yu Q; Jiang L; Liao R; Zhao W; Su B
    Front Immunol; 2021; 12():650184. PubMed ID: 33868288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (activated) in the treatment of severe sepsis.
    Vincent JL
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients.
    Hook KM; Abrams CS
    Clin Transl Sci; 2012 Feb; 5(1):85-92. PubMed ID: 22376264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise of protein C.
    Griffin JH; Fernández JA; Mosnier LO; Liu D; Cheng T; Guo H; Zlokovic BV
    Blood Cells Mol Dis; 2006; 36(2):211-6. PubMed ID: 16464623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Activated protein C, coagulation, inflammation and treatment of severe sepsis].
    Ott A
    Ned Tijdschr Geneeskd; 2001 Nov; 145(45):2196-7. PubMed ID: 11727624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.